News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
702,438 Results
Type
Article (64458)
Company Profile (376)
Press Release (637604)
Section
Business (202263)
Career Advice (2381)
Deals (33942)
Drug Delivery (87)
Drug Development (82744)
Employer Resources (145)
FDA (15940)
Job Trends (14637)
News (341446)
Policy (30788)
Tag
Academia (2849)
Alliances (52209)
Alzheimer's disease (1310)
Approvals (15872)
Artificial intelligence (142)
Bankruptcy (304)
Best Places to Work (11410)
Biotechnology (263)
Breast cancer (123)
Cancer (1121)
Cardiovascular disease (98)
Career advice (1996)
Cell therapy (254)
Clinical research (65037)
Collaboration (414)
Compensation (181)
COVID-19 (2659)
C-suite (101)
Data (1135)
Diabetes (149)
Diagnostics (6181)
Earnings (78636)
Employer resources (128)
Events (108119)
Executive appointments (320)
FDA (16475)
Funding (361)
Gene therapy (180)
GLP-1 (621)
Government (4027)
Healthcare (18413)
Infectious disease (2740)
Inflammatory bowel disease (116)
Interviews (430)
IPO (16033)
Job creations (3628)
Job search strategy (1710)
Layoffs (421)
Legal (6930)
Lung cancer (174)
Manufacturing (186)
Medical device (13072)
Medtech (13076)
Mergers & acquisitions (18017)
Metabolic disorders (421)
Neuroscience (1606)
NextGen Class of 2024 (6478)
Non-profit (4580)
Northern California (1470)
Obesity (234)
Opinion (216)
Patents (106)
People (57414)
Phase I (20351)
Phase II (28628)
Phase III (21216)
Pipeline (460)
Postmarket research (2785)
Preclinical (9232)
Radiopharmaceuticals (257)
Rare diseases (224)
Real estate (6045)
Regulatory (21115)
Research institute (2603)
Resumes & cover letters (361)
Southern California (1301)
Startups (3789)
United States (13538)
Vaccines (596)
Weight loss (183)
Date
Today (121)
Last 7 days (806)
Last 30 days (3850)
Last 365 days (36339)
2024 (33311)
2023 (40734)
2022 (51966)
2021 (56376)
2020 (54351)
2019 (46650)
2018 (35367)
2017 (33676)
2016 (33464)
2015 (39626)
2014 (32886)
2013 (28952)
2012 (29675)
2011 (29830)
2010 (28183)
Location
Africa (916)
Arizona (158)
Asia (42210)
Australia (7392)
California (3334)
Canada (1263)
China (252)
Colorado (146)
Connecticut (158)
Europe (96215)
Florida (457)
Georgia (116)
Illinois (333)
Indiana (184)
Kansas (101)
Maryland (586)
Massachusetts (2645)
Michigan (165)
Minnesota (277)
New Jersey (949)
New York (961)
North Carolina (777)
Northern California (1470)
Ohio (145)
Pennsylvania (806)
South America (1200)
Southern California (1301)
Texas (459)
Utah (93)
Washington State (373)
702,438 Results for "galderma research and development llc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
ASDS 2024: New Phase III READY-4 Data Demonstrate Long-Term Safety and Efficacy of Galderma’s RelabotulinumtoxinA (Relfydess™)
October 21, 2024
·
9 min read
Press Releases
BioIVT LLC and KRISHGEN BioSystems Announce Exclusive Commercial Agreement to Enhance Clinical Research in South Asia
November 7, 2024
·
3 min read
FDA
The Highly Anticipated FDA Approvals of Galderma’s Nemolizumab and Eli Lilly’s Lebrikizumab are Expected to Shift Dermatologists’ Perceptions of the Atopic Dermatitis Market
September 9, 2024
·
4 min read
Press Releases
Galderma Reaffirms Its Leadership in Dermatology With Extensive Presence at EADV 2024
September 17, 2024
·
5 min read
Immunology and inflammation
Galderma’s IL-31 Injection Wins FDA Approval for Skin Disorder Prurigo Nodularis
The Swiss company’s monoclonal antibody Nemluvio is also undergoing regulatory review for atopic dermatitis, which is a potentially larger market for the first-in-class IL-31 blocker.
August 13, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Sleep Apnea Pill: Quantum Research Survey Shows Sleep Apnea Patients Seeking CPAP Alternatives
A new survey conducted by Quantum Research Group, LLC finds that more than half of patients diagnosed with sleep apnea are not satisfied with their current treatment. Nearly 70 percent of patients express a willingness to switch to a prescribed pill-form treatment.
September 9, 2024
·
4 min read
Press Releases
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
November 8, 2024
·
6 min read
Galderma @ AAD 2024: New Data Demonstrate the Long-Term Efficacy of Nemolizumab in Prurigo Nodularis and Its Durability in Atopic Dermatitis
Galderma announced new data demonstrating nemolizumab’s long-term and increasing efficacy on skin lesions and other symptoms in prurigo nodularis through to week 52 in the OLYMPIA LTE study.
March 10, 2024
·
9 min read
Drug Development
TOXINS 2024: Galderma’s Phase III RelabotulinumtoxinA Results Demonstrate Positive Efficacy and Long Duration of Effect When Treating Frown Lines and Crow’s Feet Simultaneously
Galderma announced positive topline results from the phase III READY-3 clinical trial investigating the use of RelabotulinumtoxinA for the treatment of glabellar lines and lateral canthal lines, either alone or simultaneously.
January 17, 2024
·
10 min read
Galderma Announces Regulatory Filing Acceptance for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in the U.S. and EU
Galderma announced that the U.S. Food and Drug Administration has accepted its Biologics License Applications for nemolizumab for the treatment of prurigo nodularis and for adolescents and adults with moderate to severe atopic dermatitis.
February 14, 2024
·
11 min read
1 of 70,244
Next
